摘要
目的研究产前应用低分子肝素对胎儿生长受限(FGR)的临床疗效及安全性。方法将医院从2017年1月至2020年1月收治的FGR产妇91例纳入研究。将其按照随机数字表法分作研究组45例和常规组46例。常规组予以常规治疗,研究组则于常规组的基础上增用低分子肝素治疗。分析两组临床疗效,治疗前后脐动脉血流参数水平,新生儿出生情况,不良妊娠结局发生情况等方面的差异。结果治疗后研究组头围(HC)、腹围(AC)、双顶径(BPD)以及胫骨长径(FL)均高于常规组(均P<0.05)。治疗后研究组搏动指数(PI)、阻力指数(RI)以及收缩期血液流速高值(S)/舒张晚期血液流速高值(D)均低于常规组(均P<0.05)。研究组新生儿出生胎龄、出生体质量、身长均高于常规组(均P<0.05)。研究组各项不良妊娠结局发生率均低于常规组(均P<0.05)。结论产前应用低分子肝素对FGR的临床疗效显著,且安全性较好,值得临床推广应用。
Objective To investigate the clinical efficacy and safety of low molecular weight heparin(LMWH)in the treatment of fetal growth restriction(FGR).Methods 91 women with FGR admitted to the hospital from January 2017 to January 2020 were included in the study.According to the random number table method,45 cases were divided into study group and 46 cases were divided into conventional group.The conventional group received conventional treatment,and the study group was treated with LMWH on the basis of the conventional group.The clinical efficacy,blood flow level of umbilical artery before and after treatment,newborn birth,adverse pregnancy outcome and other aspects of the two groups were analyzed.Results Head circumference(HC),abdominal circumference(AC),double top diameter(BPD)and tibial length diameter(FL)of the treatment group were all higher than those of the control group(all P<0.05).After treatment,pulse index(PI),resistance index(RI)and high systolic blood velocity(S)/high late diastolic blood velocity(D)in the study group were all lower than those in the conventional group(all P<0.05).The fetal age,birth mass and body length of newborns in the study group were all higher than those in the conventional group(all P<0.05).The incidence of adverse pregnancy outcomes in the study group was lower than that in the conventional group(all P<0.05).Conclusion The application of low molecular weight heparin in prenatal treatment of FGR has a significant clinical effect,and the safety is good,worthy of clinical application.
作者
魏美兰
WEI Mei-lan(Department of Obstetrics,the Sixth People's Hospital of Huizhou,Huizhou,Guangdong 516211)
出处
《智慧健康》
2021年第23期105-107,共3页
Smart Healthcare
关键词
胎儿生长受限
低分子肝素
临床疗效
安全性
不良妊娠结局
Fetal growth restriction
Low molecular weight heparin
Clinical efficacy
Security
Adverse pregnancy outcome
